These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 3768255)

  • 21. Acetylator phenotype and congenital malformations.
    Stoll C; Roth MP; Dott B; Doumit N; Alembik Y; Welsch M; Imbs JL
    Eur J Clin Pharmacol; 1989; 36(2):151-3. PubMed ID: 2721540
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Kinetic discrimination of three sulfamethazine acetylation phenotypes.
    Chapron DJ; Kramer PA; Mercik SA
    Clin Pharmacol Ther; 1980 Jan; 27(1):104-13. PubMed ID: 7351110
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ethanol-induced increase in drug acetylation in man and isolated rat liver cells.
    Olsen H; Mørland J
    Br Med J; 1978 Nov; 2(6147):1260-2. PubMed ID: 709306
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Drug acetylation and expression of lupus erythematosus.
    Marsden JR; Mason GG; Coburn PR; Rawlins MD; Shuster S
    Eur J Clin Pharmacol; 1985; 28(4):387-90. PubMed ID: 4029245
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Acetylator phenotyping with sulphadimidine in patients receiving isoniazid.
    Ylitalo P; Auterinen L; Marttinen A; Koivula T
    Int J Clin Pharmacol Res; 1984; 4(2):141-4. PubMed ID: 6469440
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A simple pharmacokinetic method for separating the three acetylation phenotypes: a preliminary report.
    Lee EJ; Lee LK
    Br J Clin Pharmacol; 1982 Mar; 13(3):375-8. PubMed ID: 7059437
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Occurrence of the fast acetylation phenotype in persons with the radicular syndrome. Preliminary report].
    Milejski P; Orzechowska-Juzwenko K; Tota B; Krzysztoń Z
    Neurol Neurochir Pol; 1987; 21(6):511-5. PubMed ID: 3449771
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hepatic acetylator phenotype in diabetes mellitus.
    Ladero JM; Arrojo A; de Salamanca RE; Gomez M; Cano F; Alfonso M
    Ann Clin Res; 1982 Aug; 14(4):187-9. PubMed ID: 7168549
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bioavailability factors of isoniazid in fast and slow acetylators, healthy volunteers.
    Augustynowicz-Kopeć E; Zwolska Z
    Acta Pol Pharm; 2002; 59(6):452-7. PubMed ID: 12669770
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of the acetylator phenotype on amrinone pharmacokinetics.
    Hamilton RA; Kowalsky SF; Wright EM; Cernak P; Benziger DP; Stroshane RM; Edelson J
    Clin Pharmacol Ther; 1986 Dec; 40(6):615-9. PubMed ID: 3780123
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The acetylator phenotypes of Saudi Arabian diabetics.
    Evans DA; Paterson S; Francisco P; Alvarez G
    J Med Genet; 1985 Dec; 22(6):479-83. PubMed ID: 4078878
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Influence of acetylator phenotype on the pharmacokinetics of a new vasodilator antihypertensive, endralazine.
    Reece PA; Cozamanis I; Zacest R
    Eur J Clin Pharmacol; 1982; 23(6):523-7. PubMed ID: 7160421
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Bioavailability of isoniazid in healthy volunteers--fast and slow INH acetylators].
    Augustynowicz-Kopeć E; Zwolska Z; Niemirowska-Mikulska H
    Pneumonol Alergol Pol; 2002; 70(3-4):167-79. PubMed ID: 12271964
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clonazepam acetylation in fast and slow acetylators.
    Miller ME; Garland WA; Min BH; Ludwick BT; Ballard RH; Levy RH
    Clin Pharmacol Ther; 1981 Sep; 30(3):343-7. PubMed ID: 7273597
    [TBL] [Abstract][Full Text] [Related]  

  • 35. N-acetylation and hydroxylation polymorphisms in type II diabetics with microvascular disturbances.
    Gawrońska-Szklarz B; Górnik W; Pawlik A; Kunicki P; Wójcicki J; Sitkiewicz D; Sych Z
    Eur J Clin Pharmacol; 1997; 51(6):431-5. PubMed ID: 9112055
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics of hydralazine, an antihypertensive and DNA-demethylating agent, using controlled-release formulations designed for use in dosing schedules based on the acetylator phenotype.
    Gonzalez-Fierro A; Vasquez-Bahena D; Taja-Chayeb L; Vidal S; Trejo-Becerril C; Pérez-Cardenas E; de la Cruz-Hernández E; Chávez-Blanco A; Gutiérrez O; Rodriguez D; Fernandez Z; Duenas-González A
    Int J Clin Pharmacol Ther; 2011 Aug; 49(8):519-24. PubMed ID: 21781652
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Acetylator phenotype in diabetic neuropathy.
    McLaren EH; Burden AC; Moorhead PJ
    Br Med J; 1977 Jul; 2(6082):291-3. PubMed ID: 871863
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Determination of the acetylator phenotype in a Northern Nigerian population.
    Fawcett IW; Gammon PT
    Tubercle; 1975 Sep; 56(3):199-201. PubMed ID: 1216338
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The potential clinical significance of the isoniazid acetylator phenotype in the treatment of pulmonary tuberculosis].
    Ellard GA
    Rev Mal Respir; 1984; 1(4):207-19. PubMed ID: 6505358
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Polymorphic acetylator phenotype and systemic lupus erythematosus.
    Johansson E; Mustakallio KK; Mattila MJ
    Acta Med Scand; 1981; 210(3):193-6. PubMed ID: 6974957
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.